Skip to main content
Toggle navigation
Login
Search
Home
Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
Sort by
#
Sort by
Title
P 01
EXTRASKELETAL EWING SARCOMA OF THE EXTREMITIES AND TRUNK IN < 25 YEARS OLD PATIENTS: A RETROSPECTIVE ANALYSIS OF A MONO-INSTITUTIONAL SERIES.
Favorite
P 02
PEDIATRIC SYNOVIAL SARCOMA: A REVIEW OF 21 CASES FROM A SINGLE INSTITUTION
Favorite
P 03
EVOLUTION OF CLINICALLY ACTIONABLE VARIANTS IN ADVANCED PEDIATRIC AND AYA BONE SARCOMAS
Favorite
P 04
THE CELL ATLAS OF CLEAR CELL SARCOMA
Favorite
P 05
COEFFICIENT OF VARIATION OF T2-WEIGHTED MRI PREDICTS THE PROGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Favorite
P 06
ONCOFERTILITY AND PREGNANCY IN ADOLESCENT AND YOUNG ADULT CANCERS: PHYSICIANS' KNOWLEDGE AND PREFERENCES IN A LARGE LOW-MIDDLE- INCOME COUNTRY
Favorite
P 07
IDENTIFYING CONCERNS OF ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS AND SURVIVORS FOLLOWING FERTIITY PRESERVATION
Favorite
P 08
PRELIMINARY CLINICAL ACTIVITY OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RAF FUSION-DRIVEN RECURRENT/PROGRESSIVE SARCOMAS
Favorite
P 09
A NOMOGRAM MODEL TO PREDICT THE OVERALL SURVIVAL OF ADOLESCENT AND YOUNG ADULT PATIENTS WITH LOCALLY ADVANCED EWING SARCOMA.
Favorite
P 10
ATEZOLIZUMAB IN JAPANESE PATIENTS WITH ADVANCED ALVEOLAR SOFT PART SARCOMA: A MULTI-CENTER, SINGLE-ARM, INVESTIGATOR-INITIATED PHASE 2 TRIAL (NCCH1907)
Favorite
P 11
LX-101, A NOVEL, CLINICAL STAGE, PAYLOAD-BEARING TARGETED THERAPY DIRECTED TO THE INSULIN-LIKE GROWTH FACTOR RECEPTOR, HAS POTENT PRECLINICAL ANTI-TUMOR ACTIVITY AGAINST PEDIATRIC SARCOMAS
Favorite
P 12
MULTIFOCAL AND DISSEMINATED SPORADIC DESMOID TUMOUR OF THE EXTREMITIES: A SPECIAL CHALLENGE
Favorite
P 13
OUTCOME OF PATIENTS WITH RELAPSED OR REFRACTORY NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMAS ENROLLED IN PHASE II COOPERATIVE GROUP CLINICAL TRIALS: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Favorite
P 14
PERCUTANEOUS CRYOABLATION OF PROGRESSING EXTRA-ABDOMINAL DESMOID TUMOURS
Favorite
P 15
INTRAOSSEOUS RHABDOMYOSARCOMA OF THE CHEST WITH FUS:TFCP2 FUSION AND GERMLINE VARIANTS IN NF1 AND SBDS: NOVEL LOCATION AND MOLECULAR CHARACTERISTICS OF A RARE TUMOR
Favorite
P 16
ALVEOLAR SOFT PART SARCOMA: PROGRESS TOWARD IMPROVEMENT IN SURVIVAL? A NATIONWIDE DATABASE STUDY IN JAPAN
Favorite
P 17
METASTASIS-SPECIFIC GENE EXPRESSION PATTERNS IN EWING SARCOMA
Favorite
P 18
RETROSPECTIVE ANALYSIS ON OUTCOMES PEDIATRIC PATIENTS WITH SARCOMA AND LUNG METASTASES STATUS POST PNEUMONECTOMY VERSUS PARTIAL LUNG RESECTION
Favorite
P 19
EXTRACELLULAR VESICLE CLICK MAGBEADS: A MULTIFACETED LIQUID BIOPSY PLATFORM FOR PEDIATRIC SARCOMAS
Favorite
P 20
CLEAR CELL SARCOMA: PATIENT REPORTED REAL WORLD EVIDENCE
Favorite
P 21
YOUNG ADULTS WITH NONMETASTATIC OPERABLE OSTEOSARCOMA TREATED PERIOPERATIVELY WITH METHOTREXATE, DOXORUBICIN AND CISPLATIN SCHEDULE, SINGLE INSTITUTION REPORT
Favorite
P 22
RECALL EXPERIENCE FOR SURVIVORS OF PEDIATRIC RHABDOMYOSARCOMA TREATED AT A SINGLE INSTITUTION BETWEEN 1970 AND 2010
Favorite
P 23
GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR
Favorite
P 24
COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Favorite
P 25
PREDICTING IMATINIB RESPONSES USING IN VITRO MODELS OF PDGFRA-MUTANT GASTROINTESTINAL STROMAL TUMOR
Favorite
P 26
PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS
Favorite
P 27
A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Favorite
P 28
RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Favorite
P 29
COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Favorite
P 30
FINANCIAL DIFFICULTIES EXPERIENCED BY DUTCH GASTROINTESTINAL STROMAL TUMOR (GIST) PATIENTS: DATA FROM A CROSS-SECTIONAL MULTICENTER STUDY
Favorite
P 31
NEOADJUVANT IMATINIB IN LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) IS EFFECTIVE AND SAFE: RESULTS FROM A PROSPECTIVE SINGLE CENTER STUDY WITH 108 PATIENTS
Favorite
P 32
IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)
Favorite
P 33
LONGITUDINAL FOLLOW UP OF GASTROINTESTINAL STROMAL TUMORS:DATA FROM THE LIFE RAFT GROUP INTERANTIONAL PATIENT REGISTRY
Favorite
P 34
RIPRETINIB IN COMBINATION WITH OTHER TKIS IN CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A MULTI-CENTER RETROSPECTIVE ANALYSIS
Favorite
P 35
GENOMIC ALTERATIONS IN ADVANCED GASTROINTESTINAL STROMAL TUMORS AS REVEALED BY COMPREHENSIVE GENOMIC PROFILING TESTS
Favorite
P 36
CLINICO-GENOMIC ANALYSIS OF KIT/PDGFRA/SDH WILD-TYPE GASTROINTESTINAL STROMAL TUMORS IDENTIFIES POTENTIAL DRIVER MUTATIONS
Favorite
P 37
DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST
Favorite
P 38
EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER RETROSPECTIVE STUDY
Favorite
P 39
MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
Favorite
P 40
LONG TERM OUTCOMES OF NEOADJUVANT IMATINIB AND SURGICAL RESECTION OF RECTAL GASTROINTESTINAL STROMAL TUMOURS
Favorite
P 41
GENOMIC ANALYSIS OF SECONDARY KIT MUTATIONS IN CHINESE PATIENTS WITH IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS USING NEXT-GENERATION SEQUENCING (NGS)
Favorite
P 42
THE EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A SINGLE-INSTITUTION ANALYSIS
Favorite
P 43
UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN AS A POTENTIAL NEXT GENERATION MOLECULAR TARGET FOR TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
Favorite
P 44
RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Favorite
P 45
THE LONG-TERM EFFECT OF IMATINIB WITH HEPATIC RESECTION OR OTHER LOCAL TREATMENT FOR GIST LIVER METASTASES
Favorite
P 46
CIRCULATING TUMOR DNA (CTDNA) ANALYSES AND RESISTANCE MECHANISMS EXPLORATION OF KIT-MUTANT GASTROINTESTINAL STROMAL TUMORS (GISTS) TREATED WITH AVAPRITINIB OR RIPRETINB
Favorite
P 47
PATIENT SURVIVAL IN METASTATIC GIST WITH IMATINIB-SENSITIVE MUTATIONS: REAL WORLD DATA FROM GERMAN REFERRAL CENTER (2008-2021)
Favorite
P 48
SIGNIFICANCE OF MONITORING PLASMA CONCENTRATION OF RIPRETINIB IN CHINESE PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Favorite
P 49
EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.
Favorite
P 50
CHARACTERIZATION OF A FAMILIAL GIST KINDRED INTOLERANT TO IMATINIB
Favorite
P 51
OAIE TRIAL IN PROGRESS: A RANDOMIZED PHASE II TRIAL ASSESSING APATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE(IE) VERSUS SINGLE IE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY OSTEOSARCOMA
Favorite
P 52
ARTEMIS-002 TRIAL IN PROGRESS: A MULTI-CENTER PHASE II TRIAL ASSESSING HS-20093 (B7-H3 ANTIBODY-DRUG CONJUGATE) FOR RELAPSED OR REFRACTORY OSTEOSARCOMA AND OTHER SARCOMAS
Favorite
P 53
CURATIVE-INTENT SURGERY FOR A SOLITARY ISOLATED BONE METASTASIS FROM EXTREMITY SARCOMA: WHO UNDERWENT METASTASECTOMY AND WHAT WAS THE PROGNOSTIC OUTCOME?
Favorite
P 54
HIGH-THROUGHPUT DRUG SCREENING IN CHONDROSARCOMA CELLS IDENTIFIES MULTIPLE EFFICIENT ANTINEOPLASTIC AGENTS
Favorite
P 55
RELATIVE WASH-IN RATE ON DYNAMIC CONTRAST-ENHANCED MRI AS A NEW PROGNOSTIC FACTOR IN PATIENTS WITH OSTEOSARCOMA; A POSSIBLE TOOL FOR PERSONALIZED SARCOMA-CARE?
Favorite
P 56
CHARACTERIZATION OF DENOSUMAB TREATMENT RESPONSE ON MR PERFUSION IN GIANT CELL TUMORS OF BONE
Favorite
P 57
REAL-WORLD EXPERIENCE OF CABOZANTINIB IN PAEDIATRIC, TEENAGE AND YOUNG ADULT (TYA) AND ADULT METASTATIC BONE SARCOMA PATIENTS FROM THE LONDON SARCOMA SERVICE (LSS)
Favorite
P 58
CHEMOTHERAPY-INDUCED EVOLUTION OF OSTEOSARCOMA REVEALED BY SINGLE-CELL RNA SEQUENCING
Favorite
P 59
CHONDROSARCOMA OF THE FLAT BONES: DIFFERENTIAL SURVIVAL BETWEEN HIGH GRADE LESIONS OF THE PELVIS AND SCAPULA
Favorite
P 60
SKIP LESIONS IN CHONDROSARCOMA: IS WHOLE BONE IMAGING NECESSARY?
Favorite
P 61
ADJACENT VENOUS TUMOR THROMBUS IN PRIMARY OSTEOSARCOMA OF THE PELVIS AND EXTREMITIES
Favorite
P 62
PROSTHESIS-ASSOCIATED SARCOMA: A REVIEW OF 8 HIGH-GRADE LESIONS ARISING AROUND A TOTAL JOINT ARTHROPLASTY IMPLANT
Favorite
P 63
EVALUATION OF LOCAL RECURRENCE AND DIAGNOSTIC DISCORDANCE IN CHONDROSARCOMA PATIENTS UNDERGOING PREOPERATIVE BIOPSY
Favorite
P 64
OSTEOSARCOMA. PATIENT-DERIVED XENOGRAFTS MODELS TO RECAPITULATE PATIENTS' CHEMORESISTANCE AND METASTATIC DISEASE
Favorite
P 65
PROFILING EXTRACELLULAR VESICLES AND NANOPARTICLES IN OSTEOSARCOMA
Favorite
P 66
PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA
Favorite
P 67
GENOMIC CHARACTERIZATION OF CHONDROSARCOMA: A RARE SARCOMA WITH CLINICAL RESPONSES TO IMMUNE CHECKPOINT INHIBITION
Favorite
P 68
METASTASIS-DIRECTED RADIOTHERAPY FOR EWING SARCOMA PATIENTS ENROLLED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)
Favorite
P 69
DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Favorite
P 70
ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Favorite
P 71
CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Favorite
P 72
CO-EXPRESSION OF LEUKOCYTE CYTOSOLIC PROTEIN 1 AND MATRIX METALLOPROTEINASES ARE INTEGRAL FOR METASTATIC PROGRESSION OF CHONDROSARCOMA
Favorite
P 73
FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH
Favorite
P 74
SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Favorite
P 75
REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Favorite
P 76
GENETIC EVIDENCE OF METACHRONOUS DEDIFFERENTIATION OF CHONDROSARCOMA AT A DISTANT SITE
Favorite
P 77
PATIENT OUTCOMES AFTER OPEN VERSUS CORE NEEDLE BIOPSY IN LOWER EXTREMITY SARCOMA
Favorite
P 78
THE CLINICAL OUTCOME OF EXTRASKELETAL MYXOID CHONDROSARCOMA
Favorite
P 79
HEAD AND NECK OSTEOSARCOMA: THE EXPERIENCE OF 52 CASES FROM A SINGLE TERTIARY INSTITUTION OVER 25 YEARS
Favorite
P 80
OPTIMIZING DOSE OF MAP THERAPY FOR CHILDREN, YOUNG ADULTS AND ADULTS WITH OSTEOSARCOMA; A SINGLE-CENTRE RETROSPECTIVE ANALYSIS
Favorite
P 81
OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Favorite
P 82
PROGNOSTIC FACTORS AND OUTCOMES OF 275 PATIENTS WITH HEAD AND NECK BONE AND SOFT TISSUE SARCOMA: A SINGLE CENTRE COHORT STUDY
Favorite
P 83
CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Favorite
P 84
CSF1R OVEREXPRESSION ACCELLERATES OSTEOSARCOMA TUMOR FORMATION AND GENERATES TUMORS WITH DECREASED IMMUNE CELL INFILTRATION
Favorite
P 85
TARGETING CD99 ELICITS EWING SARCOMA CELL PHAGOCYTOSIS BY UNDIFFERENTIATED AND M2-LIKE MACROPHAGES AND INDUCES MACROPHAGE POLARIZATION TOWARD A M1-LIKE PHENOTYPE
Favorite
P 86
DECIPHERING CELL-MATRIX INTERACTIONS IN OSTEOSARCOMA RESPONSE TO CHEMOTHERAPY IN A 3D TISSUE-ENGINEERED IN VITRO MODEL
Favorite
P 87
ANGIOSARCOMA OF THE ILIUM TREATED WITH HEMIPELVECTOMY AND HIP TRANSPOSITION FOLLOWED BY POSTOPERATIVE CHEMOTHERAPY WITH PAZOPANIB: A CASE REPORT
Favorite
P 89
GENERATION OF CHONDROCYTE-DERIVED MOUSE OSTEOSARCOMA MODELS - TRACKABLE SYSTEMS TO DELINEATE ONCOGENIC AND METASTATIC ENVENTS PRIOR TO TUMOROGENESIS
Favorite
P 90
RESULTS FROM AN INTERNATIONAL SURVEY OF BONE SARCOMA PATIENTS
Favorite
P 91
BLOOD TRANSFUSION AND SURVIVAL AMONG CHILD, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH OSTEOSARCOMA: A RETROSPECTIVE COHORT STUDY
Favorite
P 92
DOSIMETRIC CHARACTERISTICS, OUTCOMES AND PROGNOSTIC FACTORS OF PATIENTS WITH EXTRACRANIAL CHORDOMAS AND CHONDROSARCOMAS TREATED WITH HIGH DOSE RADIOTHERAPY: A LARGE SINGLE INSTITUTION COHORT
Favorite
P 93
INDETERMINATE CHEST LESIONS IN PATIENTS WITH BONE SARCOMA INCIDENTAL FINDING VERSUS METASTATIC DISEASE
Favorite
P 94
DEVELOPING NOVEL OLIGONUCLEOTIDE THERAPIES TO MODULATE INSULIN RECEPTOR ALTERNATIVE SPLICING IN PEDIATRIC BONE SARCOMAS
Favorite
P 95
LONG-TERM OUTCOMES OF PATIENTS DIAGNOSED WITH CHORDOMA OF THE SACRUM
Favorite
P 96
LEPTOMENINGEAL RECURRENCE OF EWING'S SARCOMA: A CASE SERIES
Favorite
P 97
AN EXPLORATORY STUDY OF AN ANTI-PD-L1/TGF-β ANTIBODY, TQB2858, IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA AND ALVEOLAR SOFT PART SARCOMA: A REPORT FROM CHINESE SARCOMA STUDY GROUP
Favorite
P 98
TUMOR IMMUNE PROFILING AND IDENTIFICATION OF IMMUNOTHERAPEUTIC TARGETS IN DEDIFFERENTIATED LIPOSARCOMA
Favorite
P 99
M2 MACROPHAGE INFILTRATION IS ASSOCIATED WITH EARLY DISEASE RECURRENCE FOLLOWING CURATIVE INTENT SURGICAL RESECTION IN SOFT-TISSUE SARCOMAS
Favorite
P 100
HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Favorite
P 101
EPIGENETIC MODULATION OF NK CELLS IMPROVES TUMOR TRAFFICKING AND ENHANCES THERAPEUTIC EFFICACY AGAINST OSTEOSARCOMA
Favorite
P 102
INTERLEUKIN-6 IN RELATION TO TUMOR BEHAVIOR AND EARLY RECURRENCE IN PRIMARY LOCALIZED SOFT TISSUE SARCOMA
Favorite
P 103
LASTING COMPLETE RESPONSE TO PEMBROLIZUMAB IN MISMATCH REPAIR DEFICIENT CARDIAC SARCOMA: A GENOMIC CHARACTERIZATION
Favorite
P 104
COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
Favorite
P 105
STING THERAPY INDUCES IMMUNOGENIC ANTI-TUMOR RESPONSES THAT ARE INDEPENDENT OF TUMOR STING EXPRESSION IN THE KP MODEL OF SOFT TISSUE SARCOMA
Favorite
P 106
CHARACTERIZATION OF AN IMMUNE COMPETENT, MURINE MODEL OF SOFT TISSUE SARCOMA
Favorite
P 107
TRABECTEDIN AUGMENTS ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY EFFICACY IN PRECLINCAL BONE SARCOMA MODELS THROUGH ENHANCED IMMUNE-MEDIATED MECHANISMS
Favorite
P 108
EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA
Favorite
P 109
INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Favorite
P 110
GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Favorite
P 111
INTERIM ANALYSIS OF A PHASE 1 STUDY USING IL12-FHAB WITH OPTIMIZED PHARMACOKINETICS
Favorite
P 112
PHASE 1/2 STUDY OF YH001, A CTLA-4 ANTIBODY WITH THE SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ENVAFOLIMAB, WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Favorite
P 113
IMMUNOSARC II: A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF DOXORUBICIN AND DACARBAZINE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED LEIOMYOSARCOMA
Favorite
P 114
PRIMARY ANALYSIS OF EFFICACY AND SAFETY OF LETETRESGENE AUTOLEUCEL (LETE-CEL) AS FIRST-LINE TREATMENT FOR UNRESECTABLE OR METASTATIC SYNOVIAL SARCOMA (SS); SUBSTUDY 1 OF IGNYTE-ESO
Favorite
P 115
EFFICACY AND CORREALTIVE ANALYSIS OF USING NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Favorite
P 116
UPDATE ON SAINT: RESULTS OF 100 PATIENTS TREATED WITH IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) AS FIRST LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Favorite
P 117
INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)
Favorite
P 118
TIM-3 QUALIFIES AS A POTENTIAL IMMUNOTHERAPEUTIC TARGET IN SPECIFIC SUBSETS OF PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (HR-STS)
Favorite
P 119
EX VIVO EXPANDED TUMOR INFILTRATING LYMPHOCYTES FOR SARCOMA TREATMENT
Favorite
P 120
THE FEASIBILITY OF CD47-BASED IMMUNOTHERAPY FOR OSTEOSARCOMA
Favorite
P 121
IMPROVING THE EFFICACY OF GD2 CHIMERIC ANTIGEN RECEPTOR T-CELLS USING HISTONE DEACETYLASE INHIBITORS
Favorite
P 122
TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA
Favorite
P 123
DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Favorite
P 124
UNLOCKING THE POTENTIAL OF MEASLES VIRUS ONCOLYTIC IMMUNOTHERAPY FOR SARCOMA: BIOMARKER DISCOVERY AND THERAPEUTIC VACCINE DEVELOPMENT
Favorite
P 125
MYELOMODULATORY TREATMENTS AUGMENT THE THERAPEUTIC BENEFIT OF ONCOLYTIC VIRUS IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS BY MODULATING THE TUMOR MICROENVIRONMENT
Favorite
P 126
CURRENT PRACTICE IN SPERMATIC CORD SARCOMA: ONCOLOGICAL TIMELINES AND OUTCOMES ACCORDING TO INITIAL RESECTIONS PERFORMED AT A LOCAL HOSPITAL VERSUS EARLY PATIENT REFERRAL TO A TERTIARY CENTRE.
Favorite
P 127
TRENDS IN CONTACTS TO THE SARCOMA UK SUPPORT LINE
Favorite
P 128
THE IMPACT OF HISPANIC ETHNICITY IN PRESENTATION AND OUTCOMES OF PATIENTS WITH SYNOVIAL SARCOMA
Favorite
P 129
LOW RATES OF SERVICE CONNECTIVITY FOR SOFT TISSUE SARCOMA (STS) AMONG ELIGIBLE VIETNAM VETERANS WITH AGENT ORANGE EXPOSURE
Favorite
P 130
THE ADOPTION OF MEDICAID EXPANSION IN THE AFFORDABLE CARE ACT IS NOT ASSOCIATED WITH STAGE AT PRESENTATION OR 5-YEAR OVERALL SURVIVAL FOR BONE OR SOFT TISSUE SARCOMAS
Favorite
P 131
PATIENT-REPORTED CONTINUED BENEFITS IN PATIENTS TREATED WITH PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR BASED ON A REAL-WORLD STUDY IN THE UNITED STATES
Favorite
P 132
SARCOMA PATEINTS' VIEWS ON USING A RISK-PREDICTION MODEL TO INFORM TREATMENT DECISIONS.
Favorite
P 133
TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Favorite
P 134
IMPACT OF THE PARTNERSHIP BETWEEN TERTIARY CENTERS AND NON-SARCOMA RADIOLOGY CENTERS.
Favorite
P 135
UNMET NEEDS IN LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC DEDIFFERENTIATED LIPOSARCOMA AND EXPECTATIONS FOR CLINICAL TRIALS: AN INTERNATIONAL DELPHI CONSENSUS STUDY
Favorite
P 136
SETTING THE INTERNATIONAL RESEARCH AGENDA FOR SARCOMA WITH PATIENTS AND CARERS: PRELIMINARY RESULTS OF PHASE II OF THE SARCOMA PATIENT ADVOCACY GLOBAL NETWORK (SPAGN) PRIORITY SETTING PARTNERSHIP
Favorite
P 137
IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON SARCOMA CARE: A SINGLE INSTITUTION EXPERIENCE
Favorite
P 138
CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Favorite
P 139
ULTRA-RARE SARCOMAS HAVE WORSE SURVIVAL COMPARED TO NON-ULTRA-RARE SARCOMAS: A NATIONAL CANCER REGISTRY STUDY
Favorite
P 140
THE PRE-DIAGNOSTIC GENERAL PRACTIONER JOURNEY OF SARCOMA PATIENTS: A REAL-WORLD DATA STUDY.
Favorite
P 141
TREATMENT VARIABILITY IN SURGICAL MANAGEMENT OF PULMONARY OLIGOMETASTATIC SOFT TISSUE SARCOMA
Favorite
P 142
THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Favorite
P 143
EXPLORING HOSPITAL VOLUME THRESHOLDS FOR IMPROVED SARCOMA TREATMENT ACROSS DIFFERENT AGE CATEGORIES IN THE UNITED STATES
Favorite
P 144
IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Favorite
P 145
OUTCOMES OF BREAST ANGIOSARCOMA UNDERGOING TREATMENT IN A SPECIALIST CENTRE
Favorite
P 146
CHARACTERIZING THE PATIENT JOURNEY TO A DIAGNOSIS OF DESMOID TUMOR: DESMOID TUMOR RESEARCH FOUNDATION NATURAL HISTORY STUDY
Favorite
P 147
UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO DAILY ACTIVITES AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE
Favorite
P 148
MOVING TOWARDS THE OPTIMIZATION OF DIAGNOSIS FOR PATIENTS WITH SARCOMA: A 10-YEAR REVIEW OF EXTERNALLY CONSULTED SARCOMA CASES IN A GENERAL ANATOMICAL PATHOLOGY SERVICE
Favorite
P 149
PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Favorite
P 150
VISUALISING SOFT TISSUE SARCOMA INCIDENCE DATA FOR PATIENT EMPOWERMENT
Favorite
P 151
DEVELOPMENT AND IMPACT OF A PRIMARY CARE SARCOMA EDUCATION MODULE FOR ENGLAND AND WALES
Favorite
P 152
EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Favorite
P 153
PRIORITY SETTING PARNTERSHIP RETROPERITONEAL SOFT TISSUE SARCOMAS
Favorite
P 154
BARRIERS TO CARE FOR MUSCULOSKELETAL TUMORS
Favorite
P 155
THE IMPACT OF THE ROLE OF A SARCOMA ADVANCED NURSE PRACTITIONER (ANP) BIOPSY CLINIC IN IMPROVING PATIENT ACCESS TO SARCOMA SERVICES
Favorite
P 156
PATIENT REPORTED EXPERIENCES WITHIN THE IRISH SARCOMA GROUP
Favorite
P 157
QUALITY OF LIFE DURING TREATMENT FOR METASTATIC SARCOMA - FEASIBILITY OF ELECTRONIC PATIENT REPORTED OUTCOMES
Favorite
P 158
SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Favorite
P 159
IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Favorite
P 160
A PROSPECTIVE STUDY EVALUATING THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH ACTIVITY LEVEL AND SLEEP PATTERNS IN SARCOMA SURVIVORS
Favorite
P 161
EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Favorite
P 162
LONG TERM SAFETY AND EFFICACY OF COMBINED DOXORUBICIN-IFOSFAMIDE CHEMOTHERAPY WITH PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY IN MARGINALLY RESECTABLE SOFT TISSUE SARCOMAS
Favorite
P 163
SELUMETINIB IN JAPANESE PEDIATRIC PATIENTS WITH SYMPTOMATIC INOPERABLE PLEXIFORM NEUROFIBROMA IN NEUROFIBROMATOSIS TYPE 1
Favorite
P 164
INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
Favorite
P 165
MIDDLE EAR RHABDOMYOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Favorite
P 166
SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
Favorite
P 167
FDG-PET-CT RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY PREDICTS LONG-TERM OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA -- 15-YEAR FOLLOW-UP
Favorite
P 168
A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEXIDARTINIB IN ASIAN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Favorite
P 169
UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Favorite
P 170
HETEROGENEITY OF PAZOPANIB ACTIVITY ACROSS SOFT TISSUE SARCOMA SUBTYPES - A RETROSPECTIVE ANALYSIS OF 303 CASES FROM A REFERENCE CENTER
Favorite
P 171
SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER
Favorite
P 172
PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS
Favorite
P 173
SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Favorite
P 174
SELISARC: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE I/II TRIAL OF SELINEXOR PLUS GEMCITABINE IN SELECTED SARCOMA SUBTYPES: RESULTS OF THE PHASE I PART
Favorite
P 175
TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Favorite
P 176
SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Favorite
P 177
ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES
Favorite
P 178
INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Favorite
P 179
PILOT STUDY OF A REMOTELY DELIVERED RESISTANCE EXERCISE TRAINING PROGRAM IN SARCOMA SURVIVORS
Favorite
P 180
HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE
Favorite
P 181
REAL-WORLD EXPERIENCE WITH LIPOSOMAL DOXORUBICIN IN METASTATIC AND LOCALLY ADVANCED SARCOMA
Favorite
P 182
UPDATED RESULTS FROM AN ONGOING PHASE 1B STUDY OF UNESBULIN (PTC596) PLUS DACARBAZINE FOR THE TREATMENT OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA
Favorite
P 183
A PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (ANN) IN SUBJECTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS (STS) WITH PULMONARY METASTASES
Favorite
P 184
PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM IN SUBJECTS WITH ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MTD/RP2D
Favorite
P 185
LONGITUDINAL MUTATIONAL ANALYSIS OF TP53 IN CIRCULATING TUMOR DNA IN THE PLASMA OF PATIENTS WITH LIPOSARCOMA IN A PHASE I STUDY OF BRIGIMADLIN (BI 907828), AN MDM2-P53 ANTAGONIST
Favorite
P 186
PATIENT REPORTED OUTCOME ASSESSMENT AND REPORTING IN RANDOMIZED CLINICAL TRIALS OF SYSTEMIC THERAPY FOR ADVANCED SOFT TISSUE SARCOMAS: A SYSTEMATIC REVIEW.
Favorite
P 187
PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Favorite
P 188
IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
Favorite
P 189
INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Favorite
P 190
DOES RESPONSE TO PRIOR CHEMOTHERAPY PREDICT OUTCOME FROM FURTHER SYSTEMIC TREATMENT IN ADVANCED LEIOMYOSARCOMA? A SINGLE UK CENTRE EXPERIENCE
Favorite
P 191
SARC024 COHORT D: PHASE 2 TRIAL OF REGORAFENIB IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RHABDOMYOSARCOMA
Favorite
P 192
ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.
Favorite
P 193
Recent Trends in Sarcoma Trials for Children in the United States
Favorite
P 194
REAL WORLD OUTCOMES OF PATIENTS TREATED WITH GEMCITABINE AND DOCETAXEL FOR ADVANCED SOFT TISSUE SARCOMA IN AN AUSTRALIAN SARCOMA CENTRE
Favorite
P 195
MULTIPLE MYXOMA EFFECTIVELY TREATED WITH PAZOPANIB - A CASE REPORT
Favorite
P 196
TOLERABILITY AND OUTCOMES FOR TREATMENT OF OLDER MYXOID LIPOSARCOMA POPULATION
Favorite
P 197
PROPRANOLOL MONOTHERAPY IN ANGIOSARCOMA - A WINDOW-OF-OPPORTUNITY STUDY (PROPANGIO)
Favorite
P 198
PERSONALIZED MULTIDISCIPLINARY MANAGEMENT OF SARCOMA IN PATIENTS WITH LYNCH SYNDROME
Favorite
P 199
PEXIDARTINIB RISK EVALUATION AND MITIGATION STRATEGY PROGRAM: 3-YEAR SAFETY DATA ASSESSMENT
Favorite
P 200
EPIDEMIOLOGY OF TENOSYNOVIAL GIANT CELL TUMOR IN THE UNITED STATES
Favorite
P 201
PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Favorite
P 202
INFLAMMATORY MYOFIBROBLASTIC TUMOUR WITH ROS1 GENE FUSIONS IN CHILDREN AND YOUNG ADOLESCENTS
Favorite
P 203
PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM
Favorite
P 204
RADIATION-INDUCED ANGIOSARCOMA OF THE BREAST: RETROSPECTIVE ANALYSIS AT A REGIONAL TREATMENT CENTRE
Favorite
P 205
PRIMARY CARDIAC SARCOMA: A RETROSPECTIVE ANALYSIS OF PRESENTATION, MANAGEMENT AND OUTCOMES
Favorite
P 206
A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Favorite
P 207
A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902
Favorite
P 208
LOW INCIDENCE OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION IN ADULT SARCOMA PATIENTS RECEIVING DOXORUBICIN AND UPFRONT DEXRAZOXANE
Favorite
P 209
PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Favorite
P 210
FINANCIAL TOXICITY ASSOCIATED WITH THE TREATMENT OF SARCOMAS: A SINGLE INSTITUTION RETROSPECTIVE-PROSPECTIVE STUDY
Favorite
P 211
AN ANALYSIS OF SELF-REPORTED DEPRESSION IN SARCOMA PATIENTS
Favorite
P 212
REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Favorite
P 213
EXPERIENCE WITH THE USE OF TRABECTEDIN IN ADVANCED SOFT TISSUE SARCOMA IN IRELAND
Favorite
P 214
SIGNIFICANT TREATMENT RESPONSE IN PATIENTS WITH PRIMARY RESECTABLE EXTREMITY MYXOID LIPOSARCOMA RECEIVING NEOADJUVANT TRABECTEDIN AND RADIATION
Favorite
P 215
IMPACT OF FRONTLINE SYSTEMIC TREATMENT CHOICE ON CLINICAL OUTCOME IN ADVANCED LEIOMYOSARCOMA: A MULTI-CENTRE RETROSPECTIVE CANSARCC STUDY
Favorite
P 216
BRAIN METASTASES IN SARCOMA: A (NOT SO) RARE EVENT. THE EXPERIENCE OF A HIGH VOLUME CENTER
Favorite
P 217
CONTEMPORARY TREATMENT PATTERNS AND OUTCOMES IN THE MANAGEMENT OF ANGIOSARCOMA IN IRELAND
Favorite
P 218
NEOADJUVANT CHEMOTHERPAY AND RADIATION DECREASES TUMOR SIZE, VIABILITY, AND RECURRENCE IN MULTIPLE LIPOSARCOMA SUBSETS
Favorite
P 219
ELECTIVE DISCONTINUATION OF SORAFENIB TREATMENT IN DESMOID TUMORS: A RETROSPECTIVE ANALYSIS WITH IMPLICATIONS FOR CLINICAL PRACTICE
Favorite
P 220
[68GA]GA-FAPI PET/CT AS NOVEL DIAGNOSTIC TOOL IN SARCOMA
Favorite
P 221
EARLY RESULTS IN NOVEL USE OF CONTRAST-ENHANCED SUSCEPTIBILITY-WEIGHTED IMAGING IN THE ASSESSMENT OF RESPONSE AND PROGRESSION IN DESMOID FIBROMATOSIS: PILOT STUDY IN A SPECIALIZED CANCER INSTITUTION
Favorite
P 222
EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Favorite
P 223
SIGNATERA CTDNA TRACKER IN SARCOMA: CLINICAL EXPERIENCE
Favorite
P 224
CO-MUTATION-DEPENDENT PROGNOSIS IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA
Favorite
P 225
PAN-SARCOMA DATABASE (PSDB): A MODEL-VIEW-CONTROLLER FRAMEWORK UTILIZING REDCAP, SHINY, AND R TO CREATE A CONTINUOUS PIPELINE OF SARCOMA DATA
Favorite
P 226
SIGNATERA TESTING TO IDENTIFY MINIMAL RESIDUAL DISEASE IN HIGH GRADE SARCOMA
Favorite
P 227
DE NOVO NATURAL LANGUAGE PROCESSING (NLP) ALGORITHM ACCURATELY IDENTIFIES MYXOFIBROSARCOMA DIRECTLY FROM PATHOLOGY REPORTS
Favorite
P 228
WHAT IS THE SIGNIFICANCE OF INDETERMINATE PULMONARY NODULES IN HIGH GRADE SOFT TISSUE SARCOMA? A RETROSPECTIVE COHORT STUDY
Favorite
P 229
ON THE VARIABILITY IN THE ANALYSIS OF APPARENT DIFFUSION COEFFICIENT ESTIMATES FOR MULTICENTER DIFFUSION MRI DATA OF RHABDOMYOSARCOMA PATIENTS
Favorite
P 230
SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Favorite
P 231
MINIMALLY INTERACTIVE SEGMENTATION OF SOFT-TISSUE TUMORS ON MRI AND CT USING DEEP LEARNING
Favorite
P 232
NOVEL MRI SCORING SYSTEM TO ASSESS OSSEOUS MALIGNANCY IN SOFT TISSUE SARCOMA PATIENTS FOLLOWING RADIOTHERAPY
Favorite
P 233
MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION
Favorite
P 234
GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Favorite
P 235
FUSION OF PREOPERATIVE IN SITU MAGNETIC RESONANCE IMAGING AND POSTOPERATIVE COMPUTED TOMOGRAPHY TO CORRELATE FUNCTIONAL IMAGING FEATURES AND PATHOLOGICAL CHARACTERISTICS OF SOFT TISSUE SARCOMA
Favorite
P 236
APOBEC MUTAGENESIS IN OSTEOSARCOMA DEVELOPMENT, PROGRESSION AND RESPONSE TO THERAPY
Favorite
P 237
SECONDARY REARRANGEMENT CREATING A PLEC-EML4-ALK DOUBLE FUSION AS A MECHANISM OF RESISTANCE TO CRIZOTINIB IN AN EML4-ALK-POSITIVE INFLAMMATORY MYOFIBROBLASTIC TUMOR
Favorite
P 238
EPIDEMIOLOGIC SURVEY OF MYXOFIBROSARCOM USING DATA FROM THE BONE AND SOFT TISSUE TUMOR REGISTRY IN JAPAN
Favorite
P 239
CANCER RADIOMIC AND PERFUSION IMAGING (CARPI) AUTOMATED FRAMEWORK: VALIDATION ON MUSCULOSKELETAL TUMORS IN A SPECIALIZED CANCER CENTER
Favorite
P 240
IDENTIFYING PATIENTS AT HIGH RISK OF HIP FRACTURE DUE TO BONE TUMORS BY COMPUTATIONAL BIOMECHANICS: A RANDOMIZED PROSPECTIVE CLINICAL STUDY
Favorite
P 241
ASSOCIATION OF ADC VALUES WITH DESMOID TUMOR SHRINKAGE DURING ACTIVE OBSERVATION
Favorite
P 242
WHOLE BODY PET/MRI FOR STAGING OF MYXOID LIPOSARCOMA
Favorite
P 243
EVALUATION OF THE USE OF WGS IN ROUTINE DIAGNOSTICS FOR BONE AND SOFT TISSUE TUMORS
Favorite
P 244
A DEEP FEW-SHOT META-LEARNING STRATEGY FOR AUTONOMOUS CLASSIFICATION OF BONE METASTASIS IN RADIONUCLIDE BONE SCANS
Favorite
P 245
IN VIVO USE OF RAMAN SPECTROSCOPY IN SOFT TISSUE SARCOMA RESECTION
Favorite
P 246
IMMUNOCOMPETENT MODELING OF PLEOMORPHIC LIPOSARCOMA
Favorite
P 247
HARNESSING EWING SARCOMA'S REPLICATION STRESS BY TARGETING DDK AND WEE1 IN COMBINATION
Favorite
P 248
FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Favorite
P 249
INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Favorite
P 250
SHARING HIGH-QUALITY SAMPLES AND DATA TO THE NF1 RESEARCH COMMUNITY: THE ROLE OF THE JOHNS HOPKINS NF1 BIOSPECIMEN REPOSITORY
Favorite
P 251
EVALUATION OF POTENTIAL TARGETS FOR FLUORESCENCE-GUIDED SURGERY IN PEDIATRIC EWING SARCOMA: A PRECLINICAL PROOF-OF-CONCEPT STUDY
Favorite
P 252
STUDY OF NUTRACEUTICAL INTERVENTION WITH HIGH PHENOLIC EXTRA VIRGIN OLIVE OIL AND CURCUMIN FOR NEUROFIBROMATOSIS TYPE 1
Favorite
P 253
THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Favorite
P 254
A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Favorite
P 255
EPIDEMIOLOGY OF NOVEL ACTIONABLE TARGETS IN SYNOVIAL SARCOMA: A TISSUE MICRO-ARRAY STUDY
Favorite
P 256
EFFICACY AND TOXICITY OF VERTEPORFIN IN COMBINATION WITH PAZOPANIB TESTED IN A PATIENT-DERIVED SYNOVIAL SARCOMA XENOGRAFT
Favorite
P 257
CHARACTERIZING THE EVOLUTION AND THERAPEUTIC RESPONSE OF UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING MOUSE MODELS
Favorite
P 258
THE CRITICALITY OF OXIDATIVE PHOSPHORYLATION IN SYNOVIAL SARCOMA METASTASIS
Favorite
P 259
LOVASTATIN INDUCES NOVEL CELL DEATH THROUGH THE IMPAIRED MITOCHONDRIA IRON UTILIZATION IN OSTEOASRCOMA CELLS.
Favorite
P 260
TARGETING HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) IN LEIOMYOSARCOMA WITH COMBINATION OF PARP INHIBITORS (PARPI) AND CHEMOTHERAPY (CTX).
Favorite
P 261
EFFICACY OF BET INHIBITORS IN SOLITARY FIBROUS TUMOR: AN IN VITRO EVALUATION
Favorite
P 262
ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Favorite
P 263
HER2 AS A POTENTIAL NOVEL THERAPEUTIC TARGET IN SOFT TISSUE SARCOMAS
Favorite
P 264
CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS AND TRABECTEDIN IN SOFT TISSUE SARCOMA: A NOVEL POTENTIAL SYNERGY?
Favorite
P 265
SELECTIVE TARGETING OF BET FAMILY EPIGENETIC REGULATORS IN ADVANCED AND METASTATIC ALVEOLAR RHABDOMYOSARCOMA
Favorite
P 266
ROMIDEPSIN DECREASES DNA DAMAGE REPAIR AND INCREASES SENSITIVITY TO CHEMOTHERAPY IN EWING SARCOMA
Favorite
P 267
NEW MOUSE MODEL OF SYNOVIAL SARCOMA BASED ON CONDITIONAL EXPRESSION IN MESENCHYMAL PROGENITORS
Favorite
P 268
IMPACT OF CELLULAR FUSION IN THE ONCOGENESIS OF LEIOMYOSARCOMAS
Favorite
P 269
PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Favorite
P 270
ALTERNATIVE SPLICING (AS) REGULATION AS A NOVEL THERAPEUTIC TARGET IN SOFT-TISSUE SARCOMA (STS)
Favorite
P 271
PHARMACODYNAMICS AND MECHANISTIC IMPACTS OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS
Favorite
P 272
A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)
Favorite
P 273
COMPARISON OF A PATIENT-DERIVED XENOGRAFTS (PDX) OF MYXOID PLEOMORPHIC LIPOSARCOMA (MPL) AND PLEOMORPHIC LIPOSARCOMA (PL) HIGHLIGHTS THE EFFECTIVENESS OF ERIBULIN IN A PDX OF MPL
Favorite
P 274
TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Favorite
P 275
GIST-BSF1: A NOVEL SCF-DEPENDENT, WILD-TYPE KIT CELL LINE PLATFORM THAT ALLOWS RAPID GENERATION OF ISOGENIC SUBLINES WITH BOTH IMATINIB-SENSITIVE AND IMATINIB-RESISTANT GENOTYPES
Favorite
P 276
REVISITING IN- AND OFF LABEL DRUGS FREQUENTLY USED IN METASTATIC GIST USING A BROAD IN VITRO PROFILING PANEL OF PRIMARY AND SECONDARY KIT AND PDGFRA-MUTANT GIST CELLS – CLINICAL IMPLICATIONS
Favorite
P 277
ANTI-GD2 SYNERGIZES WITH HYPOXIA PATHWAY TARGETING TO BLOCK OSTEOSARCOMA CELL PROLIFERATION AND MIGRATION.
Favorite
P 278
CLINICAL MARKERS PREDICTIVE OF TRABECTEDIN RESPONSE IN SOFT TISSUE SARCOMA
Favorite
P 279
PROTEIN PHOSPHATASE 2 A INHIBITION AS A MECHANISM TO ENHANCE DOXORUBICIN ACTIVITY
Favorite
P 280
A CELL-BASED COMPOUND SCREENING IDENTIFIES AGENTS THAT SYNERGIZE WITH EVEROLIMUS IN SARCOMA
Favorite
P 281
FIVE DAY SPACING OF TWO FRACTIONATED ABLATIVE RADIOTHERAPIES ENHANCES ANTITUMOR IMMUNITY IN FIBROSARCOMA CELL LINE
Favorite
P 282
AN EMBRYONIC ZEBRAFISH XENOGRAFT MODEL OF RHABDOMYOSARCOMA REVEALS GENOTYPE DEPENDENT TUMOUR VASCULARISATION DYNAMICS AND RESPONSE TO ANTI-ANGIOGENIC RECEPTOR TYROSINE KINASE INHIBITORS
Favorite
P 283
A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Favorite
P 284
VALIDATING A NOVEL MICROFLUIDIC PLATFORM AS AN EX VIVO TUMOUR MODEL FOR SARCOMA DRUG DISCOVERY
Favorite
P 285
TUMOUR-INFILTRATING MAST CELLS IN ANGIOSARCOMAS CORRELATE WITH CLINCIAL PHENOTYPES AND IMMUNO-ONCOLOGY PATHWAYS
Favorite
P 286
EPIGENETIC MECHANISMS AND SIGNATURES OF SARCOMA PROGRESSION AND METASTASIS
Favorite
P 287
ESTABLISHMENT AND GENOMIC VALIDATION OF NOVEL PATIENT-DERIVED XENOGRAFT MODELS FOR DRUG DISCOVERY IN GASTROINTESTINAL STROMAL TUMOR
Favorite
P 288
EVALUATION OF ATR AND WEE1 INHIBITORS COMBINED WITH NANO-LIPOSOMAL IRINOTECAN IN A LARGE COHORT OF RHABDOMYOSARCOMA XENOGRAFTS USING A TWIN MOUSE PRECLINICAL TRIAL DESIGN
Favorite
P 289
IDENTIFICATION OF EFFECTIVE THERAPEUTIC COMBINATIONS WITH THE NUCLEAR EXPORT PROTEIN INHIBITOR, SELINEXOR, IN PEDIATRIC SOLID TUMORS
Favorite
P 290
PRE-CLINICAL STUDY OF TUMOR TREATING FIELDS (TTFIELDS) ALONE OR IN CONJUNCTION WITH SYSTEMIC THERAPIES IN SELECTED BONE- AND SOFT-TISSUE SARCOMAS
Favorite
P 291
DEVELOPMENT OF A LIVE TISSUE SARCOMA BIOBANK TO SUPPORT THE CREATION OF PATIENT-DERIVED TRANSLATIONAL MODELS
Favorite
P 292
APPLICATION OF HIGH-INTENSITY FOCUSED ULTRASOUND THERMAL ABLATION AND BOILING HISTOTRIPSY WITH CHECKPOINT INHIBITORS IN A MURINE MODEL OF OSTEOSARCOMA: AN IN-DEPTH STUDY
Favorite
P 293
GENERATION OF A SPONTANEOUS IMMUNOCOMPETENT MOUSE MODEL OF LIPOSARCOMA
Favorite
P 294
DNA-DAMAGE REPAIR DYSREGULATION AND CHEMOTHERAPY RESPONSE IN SARCOMA MODELS
Favorite
P 295
ORTHOTOPIC XENOGRAFTS OF PAIRED SARCOMA PRIMARY TUMOUR, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY IN A MINIMAL RESIDUAL DISEASE MODEL
Favorite
P 296
EX VIVO SARCOMA CELL CULTURES FROM PAIRED PRIMARY, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY
Favorite
P 297
UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Favorite
P 298
EVALUATING THE PHOTOTHERMAL AND CYTOTOXIC PROPERTIES OF INDOCYANINE GREEN IN VITRO FOR INTRAOPERATIVE PHOTOTHERMAL THERAPY IN SARCOMA
Favorite
P 299
EXPLORING THE IMMUNOLIGHT MECHANISM OF ACTION IN A GENETICALLY ENGINEERED MOUSE MODEL OF SOFT TISSUE SARCOMA
Favorite
P 300
ANTI-TUMOR ACTIVITY OF PARP7 INHIBITOR RBN-2397 IN SOFT-TISSUE SARCOMAS
Favorite
P 301
REDUCING THE INVASIVE POTENTIAL OF DEDIFFERENTIATED LIPOSARCOMA BY TARGETING ALTERNATIVE RNA SPLICING MACHINERY
Favorite
P 303
PRECLINICAL EVALUATION OF PARP1 SELECTIVE INHIBITOR AZD5305 IN COMBINATION WITH DNA DAMAGING AGENTS IN EWING SARCOMA ORTHOTOPIC XENOGRAFT MODELS
Favorite
P 304
A COMPARATIVE ANALYSIS OF METABOLIC FLEXIBILITY IN OSTEOSARCOMA CELLS
Favorite
P 305
A NEW MOUSE MODEL FOR TESTING SPLICE-SWITCHING THERAPIES IN RHABDOMYOSARCOMA
Favorite
P 306
USE OF PENCIL BEAM SCANNING PROTON RADIOTHERAPY IN MOBILE SPINE CHORDOMAS
Favorite
P 307
IS RADIOTHERAPY NECESSARY FOR MANAGEMENT OF LOW GRADE MYXOID LIPOSARCOMA? A SYSTEMATIC REVIEW
Favorite
P 308
OPTIMAL BIOLOGIC EFFECTIVE DOSE OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC AND RECURRENT SARCOMA
Favorite
P 309
CLINICAL PATHOLOGICAL CHARACTERISTICS, PATTERN OF CARE AND SURVIVAL OF NON-METASTATIC BREAST ANGIOSARCOMA
Favorite
P 310
PREOPERATIVE RADIOTHERAPY WITH HYPERTHERMIA IN RECURRENT AND RADIATION-INDUCED SARCOMAS: RESULTS OF A PHASE 2 CLINICAL TRIAL
Favorite
P 311
ROBUST VMAT TREATMENT PLANNING FOR EXTREMITY SOFT TISSUE SARCOMAS
Favorite
P 312
MANAGEMENT OF ADULT HEAD AND NECK SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
Favorite
P 313
SPACIALLY-FRACTIONATED RADIOTHERAPY (LATTICE) TREATMENT IN INOPERABLE NON-EXTREMITY BULKY SOFT-TISSUE SARCOMAS
Favorite
P 314
PRE-OPERATIVE RADIATION THERAPY INCREASES ADHERENCE IN PATIENTS WITH HIGH-RISK EXTREMITY SOFT TISSUE SARCOMA
Favorite
P 315
SCALP VOLUMETRIC MODULATED ARC THERAPY USING 3D MILLED BOLUS: DOSIMITRY, TOXICITY AND OUTCOMES
Favorite
P 316
THE ROLE OF RADIOTHERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A MULTICENTER COHORT STUDY
Favorite
P 317
PROGNOSTIC FACTORS, CLINICAL AND TOXICITY OUTCOMES FROM A LARGE COHORT OF PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE RADIATION THERAPY
Favorite
P 318
DEVELOPMENT OF NOVEL OUTLINING GUIDELINES FOR NORMAL TISSUE STRUCTURES FOR LIMB SOFT TISSUE SARCOMA.
Favorite
P 319
HYPO-FRACTIONATED RADIATION THERAPY FOR THE EXTREMITY SOFT TISSUE SARCOM IN ELDERLY AND DISABLED.
Favorite
P 320
A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
Favorite
P 321
IDENTIFYING RISK FACTORS FOR REDUCTION OF PROTON THERAPY RE-PLANS FOR PAEDIATRIC PATIENTS WITH PELVIC SARCOMAS
Favorite
P 322
STEREOTACTIC BODY RADIOTHERAPY IN METASTATIC SARCOMA
Favorite
P 323
PERIPHERAL NEUROPATHY FOLLOWING INTRA-OPERATIVE RADIOTHERAPY FOR EXTREMITY SOFT TISSUE SARCOMA: A SINGLE INSTITUTION EXPERIENCE
Favorite
P 324
EVALUATING THE ROLE OF ADJUVANT RADIATION AFTER WIDE LOCAL EXCISION OF PLEOMORPHIC DERMAL SARCOMA
Favorite
P 325
OUTCOMES AFTER MODERN THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY AND INTENSITY MODULATED RADIOTHERAPY TO TREAT SARCOMAS ARISING IN THE HAND: A RETROSPECTIVE SERIES
Favorite
P 326
CARBON-ION RADIOTHERAPY FOR UNRESECTABLE PELVIC SARCOMAS/CHORDOMAS
Favorite
P 326
MOLECULAR LANDSCAPE OF ENDOMETRIAL STROMAL SARCOMA IN A LARGE REAL-WORLD PATIENT COHORT
Favorite
P 327
LEARNING CURVE ANALYSIS IN RETROPERITONEAL SARCOMA SURGERY
Favorite
P 328
REAL-LIFE EXPERIENCE OF PAZOPANIB IN PATIENTS WITH ADVANCED UTERINE LEIOMYOSARCOMA (U-LMS) FROM TWO REFERRAL ITALIAN CENTERS
Favorite
P 329
DISTANT METASTASIS IN RETROPERITONEAL LEIOMYOSARCOMA: TUMOR SIZE, GRADE AND MORE?
Favorite
P 330
TREATMENT VARIATIONS, OUTCOMES AND PATTERNS OF RECURRENCE AFTER CURATIVE INTENT TREATMENT FOR PRIMARY RETROPERITONEAL SARCOMAS IN LATIN AMERICA. FIRST COLLABORATIVE LATAMSARC STUDY
Favorite
P 331
MUSCULAR DEDIFFERENTIATION IN DEDIFFERENTIATED LIPOSARCOMA: INSIGHTS INTO INFLAMMATORY PROFILES USING THE NEUTROPHIL/LYMPHOCYTE RATIO AND PROGNOSTIC IMPLICATIONS
Favorite
P 332
SURGICAL OUTCOMES OF RETROPERITONEAL LIPOSARCOMA - SINGLE INSTITUTIONAL STUDY N JAPAN -
Favorite
P 333
SYSTEMIC TREATMENT IN INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A SINGLE INSTITUTION RETROSPECTIVE CASE SERIES ANALYSIS
Favorite
P 334
CHARACTERISTICS AND OUTCOMES FOR PATIENTS IN THE UNITED STATES WITH DEDIFFERENTIATED LIPOSARCOMA FROM A REAL-WORLD DATA SET
Favorite
P 335
EXTRACELLULAR VESICLE MDM2 DNA AS A BIOMARKER OF TUMOR PRESENCE AND RECURRENCE IN RETROPERITONEAL LIPOSARCOMA
Favorite
P 336
EVOLUTION AND PURSUIT OF EXCELLENCE IN SARCOMA MANAGEMENT IN AN ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Favorite
P 337
CLINICAL OUTCOME OF THE PATIENTS WITH HIGH GRADE UTERINE SARCOMA: A SINGLE CENTRE REAL WORLD EXPERIENCE
Favorite
P 338
PREOPERATIVE RADIATION THERAPY IS NOT ASSOCIATED WITH ADVERSE POSTOPERATIVE OUTCOMES IN PATIENTS WITH RETROPERITONEAL SARCOMA
Favorite
P 339
QUALITY OF SURGERY AND OUTCOME FOR GIANT RETROPERITONEAL LIPOSARCOMA TREATED WITHIN SEMI-ABDOMINAL EN BLOC RESECTION USING VASCULAR PRIORITY CENTRAL APPROACH-A RETROSPECTIVE COHORT
Favorite
P 340
CENTRAL BOOST RADIATION THERAPY CAN ACHIEVE DURABLE LOCAL RESPONSE IN UNRESECTABLE RETROPERITONEAL SARCOMA
Favorite
P 341
A PHASE 1B STUDY TO EVALUATE PREOPERATIVE ERIBULIN IN COMBINATION WITH RADIATION IN RETROPERITONEAL SARCOMA
Favorite
P 342
THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Favorite
P 343
STEREOTACTIC BODY RADIATION THERAPY (SBRT) IN ADVANCED/RECURRENT RETROPERITONEAL SARCOMA: PRELIMINARY RESULTS
Favorite
P 345
CLINICIAN SURVEY - CURRENT GLOBAL PRACTICE FOR SARCOMA SURVEILLANCE FOLLOWING RESECTION OF PRIMARY RETROPERITONEAL, ABDOMINAL, AND PELVIC SARCOMA
Favorite
P 346
DETECTION OF GERMLINE VARIANTS IN PATIENTS DIAGNOSED WITH SOFT TISSUE SARCOMA USING EXPANDED
Favorite
P 347
INCIDENCE AND TIMING OF RECURRENCE AFTER ADJUVANT PALBOCICLIB IN COMPLETELY RESECTED RETROPERITONEAL LIPOSARCOMA
Favorite
P 348
RESECTION OF RECURRENT RETROPERITONEAL SOFT TISSUE SARCOMAS: ARE INTENSIVE MULTIMODAL TREATMENTS ASSOCIATED WITH INCREASED PERIOPERATIVE MORBIDITY?
Favorite
P 349
THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN (UPARAP) IS AN ATTRACTIVE TARGET FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES FOR TREATMENT OF MESENCHYMAL MALIGNANCIES
Favorite
P 350
LIVER ANGIOSARCOMA IS ASSOCIATED WITH ARISTOLOCHIC ACID EXPOSURE AND HAS A DISTINCT TELOMERE MAINTENANCE MECHANISM
Favorite
P 351
TARGETING ANDROGEN RECEPTOR IN OSTEOSARCOMA CELLS WITH VARYING METASTATIC POTENTIAL
Favorite
P 352
DETERMINING THE CONTRIBUTIONS OF STAT1 TO THE UPS ANTI-TUMOR MICROENVIRONMENT
Favorite
P 353
UPDATED EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Favorite
P 354
ROLE OF APPARENT DIFFUSION COEFFICIENT (ADC) MAP-BASED FIRST AND HIGH-ORDER RADIOMIC FEATURES IN DISCRIMINATING SACRAL CHORDOMAS AND CHONDROSARCOMAS WITH OVERLAPPING CONVENTIONAL IMAGING FEATURES
Favorite
P 355
FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE
Favorite
P 356
BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITIES SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.
Favorite
P 357
APPARENT DIFFUSION COEFFICIENT (ADC) HIGH-ORDER RADIOMICS OF BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.
Favorite
P 358
CONTRAST-ENHANCED SUSCEPTIBILITY IMAGING (CE-SWI) MORPHOLOGIC, FIRST & HIGH-ORDER RADIOMIC FEATURES VALUE IN ASSESSING TREATMENT RESPONSE IN EXTREMITY SOFT-TISSUE UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Favorite
P 359
ROLE OF PERFUSION WEIGHTED IMAGING WITH DYNAMIC CONTRAST ENHANCED (PWI/DCE) FOR THE TREATMENT ASSESSMENT OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Favorite
P 360
TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE
Favorite
P 361
MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Favorite
P 362
IDENTIFICATION OF A NOVEL INTERACTOR OF ENDOGENOUS SS18-SSX THROUGH MASS SPECTOMETRY-BASED ANALYSIS IN SYNOVIAL SARCOMA CELLS
Favorite
P 363
Β-CATENIN MUTATIONS AND TRANSCRIPTOMIC REPROGRAMMING IN DESMOID FIBROMATOSIS (DF)
Favorite
P 364
EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
Favorite
P 365
MULTIMODAL ANALYSIS OF NUCLEAR AND GENOMIC ORGANIZATION IN RHABDOMYOSARCOMA AND NORMAL MYOGENIC CELLS
Favorite
P 366
SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)
Favorite
P 367
CHARACTERIZING HYPOXIA AND ASSOCIATED MOLECULAR FEATURES IN EXTREMITY SOFT TISSUE SARCOMA
Favorite
P 368
DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS
Favorite
P 369
MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA
Favorite
P 370
SYNOVIAL SARCOMA; ROLE OF ADJUVANT CHEMOTHERAPY IN SURGICALLY TREATED PATIETNS WITH NO METASTASIS; A SEER STAT ANALYSIS.
Favorite
P 371
DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Favorite
P 372
COPY NUMBER GAIN OF MDM2 IN ROD-SHAPED CHROMOSOMES PROVIDES CLUES TO EARLY STAGES IN CIRCULARIZED GENE AMPLIFICATION IN LIPOSARCOMA
Favorite
P 373
DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?
Favorite
P 374
ARHGEF4 EXPRESSION IN SOFT TISSUE SARCOMA CORRELATES WITH LOCAL GROWTH PATTERN AND LOCAL RECURRENCE: COMPREHENSIVE GENOMIC ANALYSIS IN SEARCH OF BIOMARKER OF LOCAL GROWTH PATTERN
Favorite
P 375
IDENTIFICATION OF METASTATIC CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA: SINGLE CELL RNA SEQUENCING AND CIBERSORT ANALYSIS
Favorite
P 376
MULTI-OMIC PROFILING OF LEIOMYOSARCOMA IDENTIFIES MARKERS PREDICTIVE OF RESPONSE TO GEMCITABINE AND DOCETAXEL
Favorite
P 377
EFFECTIVENESS OF INTERVENTIONAL RADIOLOGY GUIDED PROCEDURES FOR LOCALLY RECURRENT AND METASTATIC SARCOMA: SINGLE INSTITUTIONAL RESULTS
Favorite
P 378
MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Favorite
P 379
THE ROLE OF EZHIP IN DRIVING AGGRESSIVE OSTEOSARCOMA
Favorite
P 380
NEXT GENERATION SEQUEINCING REVEALS TARGETABLE MUTATIONS IN MULTIPLE SARCOMA HISTOLOGIES
Favorite
P 381
THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Favorite
P 382
NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
Favorite
P 383
AI ANALYSIS SHOWS ENHANCED CCNG1 ONCOGENE EXPRESSION IN SARCOMA TUMORS AND SUPPORTS THE USE OF DELTAREX-G, A CCNG1 INHIBITOR, AS PLATFORM THERAPY FOR ADVANCED SARCOMA
Favorite
P 384
SYSTEMATIC LITERATURE AND CLINICAL TRIAL REVIEW SHOWS TARGETABLE KINASE FUSIONS ARE COMMON IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SOFT TISSUE SARCOMAS BUT CLINICAL TRIAL OPPORTUNITIES REMAIN RARE
Favorite
P 385
FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
Favorite
P 386
GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Favorite
P 387
CLINICAL CHARACTERIZATION OF PATIENTS WITH LEIOMYOSARCOMA HARBORING THE R337H TP53 GERMINATIVE ALTERATION (LI-FRAUMENI SYNDROME) AND THE PROGNOSTIC IMPLICATION USING A PROPENSITY-SCORE MATCHED COHORT
Favorite
P 389
OSTEOBLASTIC-GENE SIGNATURE TO PREDICT SURVIVAL IN PEDIATRIC OSTEOSARCOMA (OS) AND TO FOLLOW PATIENTS TOWARDS LIQUID BIOPSY: A COLLABORATIVE WORK IN OS2006 PROTOCOL.
Favorite
P 390
NOVEL ISOFORM DISCOVERY IN SARCOMA USING FULL-LENGTH PACBIO ISO-SEQ
Favorite
P 391
THE EXPRESSION OF PVR AND ITS CLINICOPATHOLOGICAL SIGNIFICANCE IN MPNST.
Favorite
P 392
IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT OF OSTEOSARCOMA
Favorite
P 393
INVESTIGATING THE ROLE OF HDACS IN THE PROGRESSION OF METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Favorite
P 394
LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Favorite
P 395
TARGETING CD44-MEDIATED IRON ENDOCYTOSIS IN DESMOID FIBROMATOSIS
Favorite
P 396
COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Favorite
P 397
A MESENCHYMAL TISSUE LANDSCAPE TO STUDY OSTEOSARCOMA TUMOR HETEROGENEITY
Favorite
P 398
INTEGRATED MULTI-OMICS APPROACH REVEALED TUMOR-ASSOCIATED TERTIARY LYMPHOID STRUCTURE LANDSCAPE IN RETROPERITONEAL LIPOSARCOMA
Favorite
P 399
CRITICAL MOLECULAR PATHWAYS ASSOCIATED WITH DIFFERENT HISTOPATHOLOGY FEATURES AND DETAILED PATTERNS OF IMMUNE CELL INFILTRATES IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE)
Favorite
P 400
THE LANDSCAPE OF GENOMIC ALTERATIONS FROM 1494 SOFT TISSUE AND BONE SARCOMAS AT MD ANDERSON CANCER CENTER
Favorite
P 401
OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Favorite
P 402
TISSUE PERFUSION AND WOUND HEALING AFTER SOFT TISSUE SARCOMA RESECTION
Favorite
P 403
THE IMPACT OF PATIENT, TUMOR, AND TREATMENT FACTORS ON SURVIVAL AND METASTASIS OUTCOMES IN PATIENTS WITH MYXOID LIPOSARCOMA
Favorite
P 404
PROTEOMIC PROFILING OF THE SOFT TISSUE SARCOMA MICROENVIRONMENT IDENTIFIES A PROGNOSTIC SIGNATURE BASED ON PROTEOGLYCAN EXPRESSION AND CD8+ TUMOUR INFILTRATING LYMPHOCYTES
Favorite
P 405
PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
Favorite
P 406
EXTENSIVE ANALYSIS OF 59 SARCOMA-RELATED FUSION GENES IDENTIFIED PAZOPANIB AS A POTENTIAL INHIBITOR TO COL1A1-PDGFB FUSION GENE
Favorite
P 407
PRECISION AND PERSONALIZED TREATMENT FOR SOFT TISSUE SARCOMAS. RESULTS OF A 10 PATIENTS SERIES WITH MOLECULAR PROFILING USING NEXT-GENERATION MASSIVE SEQUENCING
Favorite
P 408
CHANGES IN COMPUTED TOMOGRAPHY FEATURES INDUCED BY BRIGIMADLIN (BI 907828) IN PATIENTS WITH LIPOSARCOMA: INSIGHTS FROM PHASE I STUDIES
Favorite
P 409
IMMUNOHISTOCHEMICAL STAINING FOR MYOGENIN, AP2 BETA AND HMGA2 PREDICT FOXO1 FUSION STATUS IN RHABDOMYOSARCOMA: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Favorite
P 410
PROTEOMICS ANALYSIS IDENTIFIES A SIGNATURE THAT IMPROVES PROGNOSTIC RISK STRATIFICATION OF THE SARCULATOR NOMOGRAM IN PATIENTS WITH SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL
Favorite
P 411
A SPATIAL TRANSCRIPTOMIC "GOOGLE MAP" OF HUMAN OSTEOSARCOMA REVEALS COMMON CELL CLUSTERS AT THE PRIMARY SITE AND PULMONARY METASTASES.
Favorite
P 412
LEIOMYOSARCOMA POLYANEUPLOID CANCER CELLS DEVELOP IN RESPONSE TO CHEMOTHERAPY AND CONTRIBUTE TO CHEMORESISTANCE
Favorite
P 413
LINKING REAL-WORLD CLINICAL AND GENOMIC DATA IN RHABDOMYOSARCOMA: LEVERAGING AACR PROJECT GENIE AS A PATH TOWARD PRECISION ONCOLOGY IN RARE CANCERS
Favorite
P 414
GENOMIC ANALYSIS OF EWING SARCOMA AND HERNIA IDENTIFIES A POSITIVE GENETIC CORRELATION AND SUGGESTS BOTH ARE LINKED TO AN HMGA2 VARIANT
Favorite
P 415
NEOADJUVANT RADIOTHERAPY MODULATES THE TUMOUR MICROENVIRONMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Favorite
P 416
THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Favorite
P 417
MULTI-OMIC CHARACTERISATION OF MOLECULAR HETEROGENEITY AND NEOADJUVANT THERAPY RESPONSE IN SYNOVIAL SARCOMAS
Favorite
P 418
GENOMIC AND IMMUNOLOGICAL PROFILING OF PRIMARY AND DISTANT METASTASES OF SOFT TISSUE SARCOMAS
Favorite
P 419
AGE ADJUSTED TRENDS IN PATIENTS WITH SYNOVIAL SARCOMA
Favorite
P 420
COMPREHENSIVE MOLECULAR PROFILING AND TUMOR MICROENVIRONMENT CHARACTERISTICS OF RADIATION-INDUCED SARCOMA.
Favorite
P 421
USING TRANSCRIPTOMICS TO IDENTIFY LEIOMYOSARCOMA PATIENTS AT RISK OF METASTASIS
Favorite
P 422
CLINICAL UTILITY OF WHOLE GENOME SEQUENCING IN SARCOMA FOR THE IDENTIFICATION OF ACTIONABLE MUTATIONS: A RETROSPECTIVE COHORT ANALYSIS
Favorite
P 423
PRIMARY GLIOSARCOMA; IMPACT OF ADJUVANT CHEMO(RADIO)THERAPY ON SURVIVAL OUTCOME
Favorite
P 424
INTERNAL TANDEM DUPLICATION OF BCOR (BCOR-ITD) ALTERS THE TUMOR EPIGENOME
Favorite
P 425
CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Favorite
P 426
MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Favorite
P 427
UNDERSTANDING THE MOLECULAR DRIVERS THAT REGULATE EWING SARCOMA CELL FATE
Favorite
P 428
COMPREHENSIVE GENOMIC PROFILING OF CIC-DUX4 SARCOMA (CDS) CELL LINES AND MODELS
Favorite
P 429
SARCOMA FUSION GENE ANALYSIS YIELDS PROMISING HLA ANTIGEN FIT IN EWING SARCOMA AND DESMOPLASTIC SMALL ROUND CELL TUMOR
Favorite
P 430
UNIQUE HISTOLOGIC MORPHOLOGY OF EWING SARCOMA CELLS THAT HARBOR TP53 MUTATIONS
Favorite
P 431
TREATMENT STRATEGY AND PROGNOSTIC FACTORS IN EXTRASKELETAL EWING SARCOMA: AN INSTITUTIONAL RETROSPECTIVE ANALYSIS
Favorite
P 432
LONG-LASTING DISEASE CONTROL WITH TRABECTEDIN IN A CASE OF METASTATIC EWSR1::PATZ1 SARCOMA
Favorite
P 433
A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.
Favorite
P 434
MECHANISMS OF CHEMORESISTANCE IN CIC-DUX4 SARCOMA AS DETERMINED BY IN VIVO FUNCTIONAL GENOMICS
Favorite
P 435
ONCOGENIC FUSION YWHAE::NUTM2 DISRUPT EP300/BCOR INTERACTION
Favorite
P 436
OUTCOME PROGNOSTICATORS IN ADOLESCENTS AND ADULTS WITH BONE SARCOMAS IN LOW-MIDDLE-INCOME COUNTRIES
Favorite
P 437
ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Favorite
P 438
ALVEOLAR RHABDOMYOSARCOMA WITH "BURKITT-LIKE" MORPHOLOGY IS ASSOCIATED WITH HIGH AMPLIFICATION OF MYCL
Favorite
P 439
THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY
Favorite
P 440
LONG TERM OUTCOMES OF EWING SARCOMA OF THE FOOT AND ANKLE
Favorite
P 441
LONG VERSUS SHORTER SCHEDULES OF VINCRISTINE, IRINOTECAN AND TEMOZOLOMIDE (VIT) FOR RELAPSED OR REFRACTORY EWING SRACOMA: A RANDOMISED CONTROLLED PHASE 2 TRIAL
Favorite
P 442
LONG-TERM OUTCOME AND RELAPSE PATTERNS IN EWING SARCOMA PATIENTS WITH EXTENSIVE LUNG/PLEURAL METASTASES AFTER A COMPLETE RESPONSE TO SYSYEMIC THERAPY
Favorite
P 443
SURGICAL RESECTION OF EXTREMITY EWING'S SARCOMA BASED ON POST-CHEMOTHERAPY TUMOUR VOLUME RESULTS IN SAFE MARGINS
Favorite
P 444
TWO CASES OF BRAIN METASTASES OF CD99 POSITIVE SMALL ROUND BLUE CELL TUMORS
Favorite
P 445
ISOTOXIC RADIOTHERAPY DOSE ESCALATION IN UNRESECTABLE PEDIATRIC EWING SARCOMA: A DOSIMETRIC FEASIBILITY STUDY
Favorite
P 446
SYNERGISTIC TARGETING OF KIF11 AND AURKA TO IMPROVE OUTCOMES FOR EWING SARCOMA
Favorite
P 447
TARGETING FOCAL ADHESION KINASE AUGMENTS THE THERAPEUTIC POTENTIAL OF BROMODOMAIN INHIBITORS IN EWING SARCOMA
Favorite
P 448
CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING
Favorite
P 449
CIC-DUX4 sarcomas: A single-center review of clinical features and molecular aberrations identified through DNA sequencing
Favorite
P 450
INVESTIGATING THE THERAPEUTIC POTENTIAL OF SMALL MOLECULE INHIBITOR INOBRODIB AS A TREATMENT ALTERNATIVE FOR CIC-DUX4 SARCOMA
Favorite
P 451
IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Favorite
P 452
SECONDARY GENOMIC LANDSCAPE OF CIC::DUX4 FUSION SARCOMAS
Favorite
P 453
ROLE OF SECOND-LINE TREATMENT IN EWING SARCOMAS WITH POOR PROGNOSIS AT DIAGNOSIS: EXPERIENCE OF A SPANISH REFERENCE CENTER.
Favorite
P 454
TREATMENT PATTERNS AND OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH EWING AND UNDIFFERENTIATED ROUND BLUE CELL SARCOMAS IN ALBERTA
Favorite
P 455
EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Favorite
P 456
SECLIDEMSTAT TREATMENT BLOCKS THE TRANSCRIPTIONAL FUNCTION OF MULTIPLE FET-FUSION PROTEINS
Favorite
P 457
LONG-TERM FOLLOW-UP OF PATIENTS WITH ATYPICAL LIPOMATOUS TUMOR (ALT) TREATED WITH MARGINAL RESECTION IN A REFERRAL CENTER
Favorite
P 458
FREQUENCY IN CHANGE OF GRADING UPON LOCAL RECURRENCE OR DISTANT METASTASIS OF SOFT TISSUE SARCOMAS.
Favorite
P 459
EXPERIENCE IN THE USE OF INDIVIDUALIZED 3D-IMPLANTS IN THE RECONSTRUCTION OF DEFECTS IN PATIENTS WITH TUMORS OF THE CHEST WALL
Favorite
P 460
IMPACT OF RESIDUAL TUMOR AFTER RE-EXCISION IN PATIENTS WITH PRIOR UNPLANNED RESECTION OF EXTREMITY AND TRUNK SOFT TISSUE SARCOMAS
Favorite
P 461
OUTCOMES FOR OLIGOMETASTATIC PULMONARY DISEASE RECURRENCE TREATED WITH SURGERY ALONE FOR PATIENTS WITH SOFT TISSUE SARCOMAS A CASE SERIES
Favorite
P 462
EXTERNAL VALIDATION OF A NOMOGRAM PREDICTING THE RISK OF POSTOPERATIVE MAJOR WOUND COMPLICATION IN SOFT TISSUE SARCOMA FOLLOWING PREOPERATIVE RADIOTHERAPY AND RESECTION
Favorite
P 463
MACHINE LEARNING CORROBORATES TRADITIONAL REGRESSION TECHNIQUES IN PREDICTING MAJOR WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION WITHOUT IMPROVEMENTS IN PREDICTIVE PERFORMANCE
Favorite
P 464
INDOCYANINE GREEN FLUORESCENCE IMAGING MAY DETECT TUMOUR RESIDUALS DURING SURGERY FOR BONE AND SOFT-TISSUE TUMOURS
Favorite
P 465
UNPLANNED EXCISION OF SYNOVIAL SARCOMA: FACTORS ASSOCIATED WITH RECURRENCE AND SURVIVAL
Favorite
P 466
INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Favorite
P 467
DOES PERIOPERATIVE RADIATION AFFECT IMPLANT SURVIVORSHIP OF PRIMARY TOTAL HIP ARTHROPLASTY IN THE SETTING OF METASTATIC BONE DISEASE: A MULTICENTER STUDY
Favorite
P 468
OPIATE USE AFTER TOTAL HIP ARTHROPLASTY FOR METASTATIC BONE DISEASE
Favorite
P 469
IMPACT OF A SPECIALIZED OUTPATIENT CLINIC ON BONE MRTASTASIS AND ITS BURDEN ON SPINE SURGEONS
Favorite
P 470
PROGNOSTIC SIGNIFICANCE OF HISTOLOGICAL SUBTYPE IN SOFT TISSUE SARCOMA WITH DISTANT METASTASIS
Favorite
P 471
IMPACT OF PRIMARY TUMOR RESECTION ON METASTASIS TO THE LUNG IN PATIENTS WITH BONE AND SOFT-TISSUE SARCOMA
Favorite
P 472
ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA). AN EARLY LOOK AT SURGICAL DATA
Favorite
P 473
GROIN PAINS: APPROACHES AND OUTCOMES FOR INGUINOFEMORAL SOFT TISSUE SARCOMAS
Favorite
P 474
PREDICTORS OF EARLY INTROWTH AND FAILURE FOLLOWING SHORT COMPRESS SPINDLE OSSEOINTEGRATION FIXATION AT THE LOWER EXTREMITIES
Favorite
P 475
PRE-PLATING PRIOR TO INTERCALARY TUMOR RESECTION AND ALLOGRAFT RECONSTRUCTION: LESSONS LEARNED
Favorite
P 476
FAVORABLE RESULTS FOLLOWING TREATMENT OF UNICAMERAL BONE CYSTS WITH DOXYCYCLINE SCLEROGRAFT TECHNIQUE
Favorite
P 477
TREATMENT OF PROXIMAL FEMUR UNICAMERAL BONE CYSTS WITH DOXYCYCLINE SCLEROTHERAPY
Favorite
P 478
TREATMENT OF CHONDROBLASTOMA WITH PERCUTANEOUS CRYOABLATION
Favorite
P 479
EXPANDABLE ENDOPROSTHESES: SHOULD WE CONSIDER NARROWING OUR INDICATIONS? A SYSTEMATIC REVIEW OF THE LITERATURE AND COMPARISON OF OUTCOMES BY AGE GROUPS
Favorite
P 480
TARGETED MUSCLE REINNERVATION FOR HIP DISARTICULATION - EVALUATION OF EARLY FUNCTIONAL OUTCOMES
Favorite
P 481
CUSTOM ADAPTERS FOR COMPRESS SPINDLE OSSEOINTEGRATION FIXATION IN REVISION LIMB SALVAGE SURGERY OF THE DISTAL FEMUR: A CASE SERIES
Favorite
P 482
COMPARISON OF RECONSTRUCTIVE TECHNIQUES FOR METASTATIC DISEASE IN THE PROXIMAL HUMERUS
Favorite
P 483
DID THE COVID-19 PANDEMIC NEGATIVELY AFFECT OUTCOMES FOR PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMAS?
Favorite
P 484
OBESITY INCREASES THE RISK OF MAJOR WOUND COMPLICATIONS FOLLOWING PELVIC RESECTION FOR BONE SARCOMA
Favorite
P 485
SUBTROCHANTERIC NON-UNION AFTER INTRAMEDULLARY NAILING DUE TO PATHOLOGICAL FRACTURE:PROXIMAL FEMORAL REPLACEMENT AS A SALVAGE APPROACH
Favorite
P 486
PRIMARY HIGH-GRADE SARCOMA OF THE SPINE: EXPERIENCE WITH 11 CASES
Favorite
P 487
EN BLOC RESECTION FOR SPINAL TUMORS: A SINGLE CENTER EXPERIENCE OF 113 CONSECUTIVE CASES
Favorite
P 488
POSTOPERATIVE DRAINAGE MANAGEMENT AND WOUND COMPLICATIONS FOLLOWING RESECTION OF LOWER LIMB SOFT TISSUE TUMORS
Favorite
P 489
SIMULTANEOUS VERSUS DELAYED FLAP RECONSTRUCTION FOLLOWING SOFT TISSUE SARCOMA RESECTION
Favorite
P 490
TOPICAL ANTIBIOTICS DECREASE INFECTIONS IN EXTREMITY SARCOMA SURGERY
Favorite
P 491
COMPARISON OF FIXATION TECHNIQUES FOR METASTATIC DISEASE OF THE HUMERUS
Favorite
P 492
BALANCE AND GAIT OUTCOMES AFTER 1-YEAR POST-OPERATIVE HEMIPELVECTOMY SURGERY
Favorite
P 493
GAIT KINEMATICS OF SARCOMA PATIENTS AT 1 YEAR POST-OPERATIVE INTERNAL HEMIPELVECTOMY SURGERY: A RETROSPECTIVE STUDY.
Favorite
P 494
WHAT IS THE EXPERIENCE OF THOSE WITH CANCER-RELATED REDUCED QUALITY OF LIFE AND ASSOCIATED PHYSICAL DISABILITIES AFTER UPPER LIMB SARCOMA TREATMENT IN ENGLAND? A NATIONAL STUDY OF OUTCOMES.
Favorite
P 495
UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO ACTIVITIES OF DAILY LIVING AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE.
Favorite
P 496
WHAT ARE THE EXPERIENCES OF BALANCE, GAIT AND NEURO-MUSCULAR CONTROL OUTCOMES AFTER PROXIMAL FEMORAL REPLACEMENTS FOR MUSCULOSKELETAL TUMOURS?
Favorite
P 497
STANMORE TUMOUR OUTCOMES PROJECT (STOMP)- USING INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH (ICF) OUTCOMES IN SARCOMA SURVIVORS. and UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO DAILY ACTIVITES AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE
Favorite
P 498
DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES: CHARACTERISTICS AND OUTCOME
Favorite
P 499
CLINICAL OUTCOMES OF TOTAL FEMORAL REPLACEMENT FOR ONCOLOGICAL INDICATIONS
Favorite
P 500
IMPROVING OUTCOMES OF INTERCALARY EWING SARCOMA RESECTIONS AND ALLOGRAFT RECONSTRUCTIONS WITH PATIENT-SPECIFIC CUTTING GUIDES AND VIRTUAL SURGICAL PLANNING
Favorite
P 501
TIBIAL DEFORMITIES AND PHYSEAL INJURY WITH DISTAL FEMORAL EXPANDABLE ENDOPROSTHESIS IMPLANTS
Favorite
P 502
SEPARATE RESECTION OF BIOPSY TRACT IN PRIMARY BONE SARCOMA: IMPLICATIONS FOR LOCAL RECURRENCE AND OVERALL SURVIVAL
Favorite
P 503
SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Favorite
P 504
WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Favorite
P 505
LOCAL RECURRENCE IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A MULTICENTER COHORT STUDY
Favorite
P 506
THE EFFECT OF TIMING BETWEEN PRE-OPERATIVE EMBOLIZATION AND SURGERY: A RETROSPECTIVE ANALYSIS OF HYPERVASCULAR BONE METASTASES
Favorite
P 507
PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Favorite
P 508
DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Favorite
P 509
GIANT CELL TUMOR OF BONE IN THE PEDIATRIC POPULATION: A RETROSPECTIVE STUDY HIGHLIGHTING CASES OF METAPHYSEAL ONLY LOCATION AND INCREASED LOCAL RECURRENCE RATES IN SKELETALLY IMMATURE PATIENTS
Favorite
P 510
PRIMARY BREAST ANGIOSARCOMA: CLINICAL AND PATHOLOGICAL FEATURES AND IMPACT ON OUTCOMES
Favorite
P 511
SIGNIFICANCE OF TIP TO APEX DISTANCE IN PATHOLOGICAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR
Favorite
P 512
PERIOPERATIVE BLOOD MANAGEMENT IN PEDIATRIC PATIENTS UNDERGOING PRIMARY OSTEOSARCOMA AND EWING SARCOMA RESECTION: A RETROSPECTIVE CASE NOTE REVIEW
Favorite
P 513
THE IMPACT OF MARGIN STATUS ON THE ONCOLOGIC OUTCOMES OF SURGICALLY TREATED DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES
Favorite
P 514
INTERSTITIAL BRACHYTHERAPY IN THE TREATMENT OF SOFT TISSUE SARCOMA: LOCAL RECURRENCE AND WOUND OUTCOMES
Favorite
P 515
ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Favorite
P 516
OUCOMES OF AGGRESSIVE RESECTION OF RADIATION INDUCED ANGIOSARCOMA OF THE BREAST
Favorite
P 517
PULMONARY METASTASECTOMY FOR SARCOMA: A SINGLE-INSTITUTION EXPERIENCE
Favorite
P 518
OUTCOMES OF NON-ANGIOSARCOMA RADIATION-ASSOCIATED SOFT TISSUE SARCOMAS OF THE CHEST
Favorite
P 519
WHAT ARE THE EXPERIENCES OF GAIT, ACTIVITY LEVELS AND PHYSICAL FUNCTIONING IN PROXIMAL FEMORAL REPLACEMENT AFTER MUSCULOSKELETAL TUMORS?
Favorite
P 520
ORTHOPEDIC MANIFESTATIONS OF LYMPHOPROLIFERATIVE NEOPLASMS
Favorite
P 521
HOW TO MANAGE ABDOMINAL PARIETECTOMY, REVIEW OF EXPERIENCE IN INSTITUT BERGONIE
Favorite
P 522
FLUORESCENCE GUIDED SURGERY WITH INDOCYANINE GREEN FOR SURGICAL RESECTION OF METASTATIC BONE AND SOFT TISSUE TUMOURS: A CASE SERIES
Favorite
P 523
IN-BETWEEN SARCOMA: A CATEGORY OF HIGH RISK OF RECURRENCE AND POOR OUTCOME
Favorite
P 524
PRESENTATION AND OUTCOMES OF EXTRASKELETAL CHONDROSARCOMAS TREATED WITH SURGICAL RESECTION
Favorite
P 525
ALL INTERNAL DISTRACTION OSTEOGENESIS AFTER TUMOR RESECTION
Favorite
P 526
EVALUATION OF THE SURGICAL MANAGEMENT OF THE SKELETON IN PATIENTS WITH OLLIER'S DISEASE AND MAFUCCI SYNDROME
Favorite
P 527
SALVAGE OF AN OSTEOARRTICULAR ALLOGRAFT RADIUS RECONSTRUCTION SINGLE BONE TRANSPOSITION WITH WRIST ARTHRODESIS FOLLOWING OSTEOSARCOMA EXCISION
Favorite
P 528
SAFETY AND TOLERABILITY OF ORAL CYCLOPHOSPHAMIDE AND SORAFENIB WITH INTRAVENOUS BEVACIZUMAB WITH THE ADDITION OF ATEZOLIZUMAB IN PEDIATRIC SOLID TUMOR PATIENTS
Favorite
P 529
THE MUSCULOSKELETAL TUMOR REGISTRY -- 2023 UPDATE AND OUTLOOK
Favorite
P 530
FIH PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF THE001 COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Favorite
P 531
ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH ADVANCED OR METASTATIC UPS OR MFS WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY
Favorite
P 532
MISTOSUS: A PHASE 2 STUDY OF ISCADOR® P IMMUNOTHERAPY FOR PATIENTS WITH RELAPSED OSTEOSARCOMA AND RESECTED PULMONARY METASTASES
Favorite
P 533
SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Favorite
P 534
NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA
Favorite
P 535
THERAGNOSTICS IN SOFT TISSUE SARCOMA USING A VASCULAR DISCRUPTION APPROACH
Favorite
P 536
PHASE 1 STUDY OF DISULFIRAM WITH COPPER GLUCONATE AND LIPOSOMAL DOXORUBICIN IN PATIENTS WITH TREATMENT REFRACTORY SARCOMAS
Favorite
P 537
TGFβ IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NATURAL KILLER CELLS WITH CHEMOTHERAPY FOR RELAPSED BONE AND SOFT TISSUE SARCOMA - NCT05634369, REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Favorite
P 538
IEUROEWING TRIAL FOR LOCALIZED AND METASTATIC EWING SARCOMA
Favorite
P 539
SARCOMA STEREOTACTIC BODY RADIOTHERAPY AND IMMUNE SYSTEM TRIAL
Favorite
P 540
PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 AND TSC2 (PRECISION I)
Favorite
P 541
ETCTN 10563: PHASE 1 STUDY OF PEPOSERTIB AND LIPOSOMAL DOXORUBICIN FOR ADVANCED OR METASTATIC LEIOMYOSARCOMA AND OTHER SARCOMAS
Favorite
P 542
ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL")
Favorite
P 543
MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Favorite
P 544
INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Favorite
P 545
NEOADJUVANT PEMBROLIZUMAB AND EFTILAGIMOD ALPHA WITH CONCURRENT RADIOTHERAPY IN PATIENTS WITH SELECTED SOFT TISSUE SARCOMA SUBTYPES (EFTISARC-NEO)
Favorite
P 546
PRELIMINARY CLINICAL RESULTS OF AN ONGOING PHASE II TRIAL: SPRINT (SARCOMA PREOPERATIVE RADIATION WITH SIMULTANEOUS INTEGRATED BOOST)
Favorite
P 547
A PHASE II TRIAL OF TAZEMETOSTAT FOR PATIENTS WITH UNRESECTABLE OR METASTATIC EPITHELIOID SARCOMA (TAZETTA TRIAL)
Favorite
P 548
A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)
Favorite
P 549
DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF AL102 FOR TREATMENT OF PROGRESSING DESMOID TUMORS: THE RINGSIDE PHASE 3 STUDY DESIGN
Favorite
P 550
ON-TRK: A NON-INTERVENTIONAL STUDY OF LAROTRECTINIB IN PATIENTS WITH TRK FUSION SOLID TUMORS
Favorite
P 551
PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT RHABDOMYOSARCOMA: A CLINICAL TRIAL IN PROGRESS FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Favorite
P 552
RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Favorite
P 553
A PHASE 1/2A OPEN-LABEL, DOSE-ESCALATION/DOSE EXPANSION SAFETY, TOLERABILITY AND PHARMACOKINETIC STUDY OF IMX-110 IN PATIENTS WITH ADVANCED SOLID TUMORS
Favorite
P 554
FIVE-YEAR OUTCOMES OF A NATIONWIDE PROSPECTIVE CLINICAL TRIAL ON ACTIVE SURVEILLENCE IN PATIENTS WITH NON-INTRAABDOMINAL DESMOID-TYPE FIBROMATOSIS
Favorite
P 555
A PILOT PHASE II STUDY TO EVALUATE THE SMALL MOLECULE TIGILANOL TIGLATE IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA: CLINICAL TRIAL IN PROGRESS
Favorite
P 556
EVALUATION OF PALBOCICLIB (IBRANCE®) IN COMBINATION WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA OR NEUROBLASTOMA
Favorite
P 557
UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Favorite
P 558
TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Favorite
P 559
PROSPECTIVE PHASE II TRIAL OF PREOPERATIVE HYPOFRACTIONATED PROTON THERAPY FOR EXTREMITY AND TRUNCAL AND TRUNCAL SOFT TISSUE SARCOMA: THE PRONTO STUDY RATIONALE AND DESIGN
Favorite
P 560
REAL-WORLD MONITORING OF PHYSICAL ACTIVITY USING AN ACCELEROMETER AFTER LOWER LIMB SURGERY FOR A SARCOMA.
Favorite
P 561
EXPERIENCE OF PHYSICAL DISABILITIES AND CANCER-RELATED QUALITY OF LIFE AFTER SPINAL TUMORS- STUDY OF A NATIONAL SURVEY IN ENGLAND.
Favorite
P 562
A PHASE 2, SINGLE ARM STUDY OF REGORAFENIB IN METASTATIC/UNRESECTABLE REFRACTORY SYNOVIAL SARCOMAS
Favorite
P 563
BALANCE, GAIT AND BIOMECHANICAL COMPENSATIONS DURING DIFFERENT SPEEDS OF WALKING AFTER TREATMENT FOR DISTAL FEMORAL MUSCULOSKELETAL TUMOURS AND ASSOCIATED LIMITATIONS ON RETURN TO NORMAL LIVING
Favorite
P 564
A PILOT STUDY OF LYSO-THERMOSENSITIVE LIPOSOMAL DOXORUBICIN AND MAGNETIC RESONANCE-GUIDED HIGH INTENSITY FOCUSED ULTRASOUND FOR TREATMENT OF RELAPSED OR REFRACTORY SOLID TUMORS
Favorite
P 565
AN EARLY PHASE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF PEEL-224 IN PATIENTS WITH ADVANCED SOLID TUMORS
Favorite
